Lomustine and Bevacizumab in Progressive Glioblastoma

Wick, Wolfgang; Gorlia, Thierry; Bendszus, Martin; Taphoorn, Martin; Sahm, Felix; Harting, Inga; A. Brandes, Alba; Taal, Walter; Dômont, Julien; Idbaïh, Ahmed; Campone, Mario; M. Clément, Paul; Stupp, Roger; Fabbro, Michel; Le Rhun, Émilie; Dubois, François; Weller, Michael; von Deimling, Andreas; Golfinopoulos, Vassilis; C. Bromberg, Jacoline; Platten, Michael; Klein, Martin; J. van den Bent, Martin

doi:10.1056/nejmoa1707358

Public

Lomustine and Bevacizumab in Progressive Glioblastoma

Published in New England Journal of Medicine • Nov 15, 2017

Authors:

Wolfgang Wick

Thierry Gorlia

Martin Bendszus

Abstract

BACKGROUND: Bevacizumab is approved for the treatment of patients with progressive glioblastoma on the basis of uncontrolled data. Data from a phase 2 trial suggested that the addition of bevacizumab to lomustine might improve overall survival as compared with monotherapies. We sought to determine w...

Subject

Lomustine

Medicine

Bevacizumab

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!